Evaluation of Butaclamol in Chronic Schizophrenic Patients

Publisher Website
Google Scholar
Abstract
In a double-blind, placebo-controlled study, an attempt was made to evaluate butaclamol in chronic schizophrenic patients using chlorpromazine (CPZ) as the standard comparative drug. With doses up to 50 mg/day, butaclamol was shown to have significant antipsychotic activity comparable to CPZ but with a much higher incidence of extrapyramidal signs. A more reasonable maintenance dose may be in the range of 5-20 mg/day. Rebound insomnia was noted again with butaclamol, which warrants further study.

This publication has 1 reference indexed in Scilit: